MAGNESIUM METALLICUM
Neuropathy
Alliance for Clinical Trials in OncologySmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Neuropathy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Tanta University | Phase 3 | BBB |
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)- Washington University School of Medicine | Phase 4 | BB |
Amitriptyline Gary Morrow | Phase 3 | BB |
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE Gary Morrow | Phase 3 | BB |
Glutathione Alliance for Clinical Trials in Oncology | Phase 3 | BB |
View all 21 →
Same molecule, other indications
MAGNESIUM METALLICUM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →